Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer
Roisín M. Connolly(Johns Hopkins University), Antonio C. Wolff(Johns Hopkins University), Michelle A. Rudek(Dana-Farber Cancer Institute), John H. Fetting(Johns Hopkins University), Ming Zhao(Sidney Kimmel Comprehensive Cancer Center), Elizabeth Garrett‐Mayer(Novartis (Switzerland)), Laurie A. Wright(Johns Hopkins University), Nancy E. Davidson(WinnMed), Vered Stearns(Johns Hopkins University), Sharyn D. Baker(The Ohio State University), Michele G. Donehower(Johns Hopkins University), Stacie C. Jeter(Johns Hopkins University), Leisha A. Emens(Johns Hopkins University)
Cited by 17
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version)
|Archives of Pathology & Laboratory Medicine|2010|1.1k
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947